Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
15 mai 2024 16h15 HE
|
Marker Therapeutics
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin’s Lymphoma who...
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
08 avr. 2024 07h00 HE
|
Marker Therapeutics
Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11th Global Summit on Hematologic Malignancies in Whistler, BC, Canada ...
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
25 mars 2024 17h45 HE
|
Marker Therapeutics
Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant treated with MT-601 (Neldaleucel) following CAR...
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
22 mars 2024 12h30 HE
|
Marker Therapeutics
HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601
22 janv. 2024 07h30 HE
|
Marker Therapeutics
HOUSTON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
08 janv. 2024 08h24 HE
|
Marker Therapeutics
Strategic prioritization of clinical programs with focus on MT-601 in patients with lymphoma MultiTAA-specific T cell therapies demonstrate clinical safety and positive clinical data across multiple...
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”
21 déc. 2023 11h00 HE
|
Marker Therapeutics
HOUSTON, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
11 déc. 2023 07h00 HE
|
Marker Therapeutics
HOUSTON, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
09 nov. 2023 17h00 HE
|
Marker Therapeutics
Announced complete response in first patient with lymphoma treated with MT-601 in Phase 1 APOLLO trial following CAR T relapse Received Orphan Drug Designation (ODD) from European Medicines Agency...
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse
11 sept. 2023 07h00 HE
|
Marker Therapeutics
Marker Therapeutics reports clinical updates in APOLLO trial for the treatment of lymphoma patients who have relapsed after anti-CD19 CAR T cell therapy Patient with Non-Hodgkin’s Lymphoma who...